Loyal is a clinical-stage veterinary medicine company dedicated to developing drugs aimed at extending the lifespan and healthspan of dogs. Their mission is to contribute to the well-being of dogs by bringing innovative solutions to market, and they have made significant progress towards gaining FDA approval for the first lifespan extension drug designed for any species, with plans to launch their first product by 2025. Loyal's team comprises a diverse group of professionals, including scientists, veterinarians, engineers, and creatives, all committed to advancing the field of veterinary medicine. The company's values emphasize taking bold risks, fostering cross-disciplinary collaboration, leading with context, and maintaining empathy and respect for all life, guiding their approach as they work to improve the care of pets and support pet owners.